Effect of Hydrocortisone on Intradialytic Hypotension: A Preliminary Investigational Study

Hussein H Alhawari, Sameeha Alshelleh, Hussam H Alhawari, Izzat Ahmad Alawwa, Saif Aldeen AlRyalat, Ahmad Mesmar, Khaled Ojjoh, Karem H Alzoubi, Hussein H Alhawari, Sameeha Alshelleh, Hussam H Alhawari, Izzat Ahmad Alawwa, Saif Aldeen AlRyalat, Ahmad Mesmar, Khaled Ojjoh, Karem H Alzoubi

Abstract

Introduction: Approximately 15 to 33% of all dialysis treatments are complicated by intradialytic hypotension (IDH). In this study, we tested the hypothesis that the intravenous administration of hydrocortisone prior to HD treatment could prevent IDH or at least decrease the drop in the blood pressure resulting from IDH.

Methods: This study was approved by our local ethics committee/IRB (2017/87) and by the Jordan Food and Drug Administration (7/clinical/18). Additionally, it is registered on ClinicalTrials.gov (NCT03465007). In this preliminary investigational study, we screened all chronic hemodialysis patients at our clinic who were 18 years of age or older (n = 82) for IDH. There were 14 patients included in the interventional part of this study; patients were given IV hydrocortisone for 3 consecutive HD sessions, followed or preceded by 3 intervention-free sessions where they were given 5 ml of saline as a placebo.

Results: The initial total sample size was 82 patients. The frequency of IDH at our clinic was 24.4%. Fourteen out of the 20 patients who were diagnosed with IDH agreed to enroll in the interventional part of our study. The mean age of the patients in the interventional part of our study was 53.5 years (±10.3). These patients included 5 (35.7%) men and 9 (64.3%) women. Upon comparing the number of hypotensive attacks with and without the hydrocortisone administration, we found a significant difference (p = 0.003) between the hydrocortisone and placebo treatments in which 12 (85.7%) patients had fewer IDH episodes with the hydrocortisone treatment than with placebo.

Conclusion: This preliminary investigational study found that the administration of a stress dose of hydrocortisone prior to hemodialysis could be an effective measure for preventing or minimizing the risk of IDH episodes. Additional prospective studies on this subject are needed. Ruling out adrenal insufficiency in patients diagnosed with IDH is also crucial.

Conflict of interest statement

All authors declare that there are no conflicts of interest.

Copyright © 2020 Hussein H. Alhawari et al.

Figures

Figure 1
Figure 1
The flowchart of the patient inclusion protocol used in this study.

References

    1. Reilly R. F. Attending rounds: a patient with intradialytic hypotension. Clinical Journal of the American Society of Nephrology . 2014;9(4):798–803. doi: 10.2215/CJN.09930913.
    1. Yamamoto K., Kobayashi N., Kutsuna T., et al. Excessive fall of blood pressure during maintenance hemodialysis in patients with chronic renal failure is induced by vascular malfunction and imbalance of autonomic nervous activity. Therapeutic Apheresis and Dialysis . 2012;16(3):219–225. doi: 10.1111/j.1744-9987.2011.01053.x.
    1. Bégin V., Déziel C., Madore F. Biofeedback regulation of ultrafiltration and dialysate conductivity for the prevention of hypotension during hemodialysis. ASAIO Journal . 2002;48(3):312–315. doi: 10.1097/00002480-200205000-00018.
    1. Kuipers J., Oosterhuis J. K., Krijnen W. P., et al. Prevalence of intradialytic hypotension, clinical symptoms and nursing interventions-a three-months, prospective study of 3818 haemodialysis sessions. BMC Nephrology . 2016;17(1) doi: 10.1186/s12882-016-0231-9.
    1. Kooman J., Basci A., Pizzarelli F., et al. EBPG guideline on haemodynamic instability. Nephrology Dialysis Transplantation . 2007;22(Supplement 2):ii22–ii44. doi: 10.1093/ndt/gfm019.
    1. Stefánsson B. V., Brunelli S. M., Cabrera C., et al. Intradialytic hypotension and risk of cardiovascular disease. Clinical Journal of the American Society of Nephrology . 2014;9(12):2124–2132. doi: 10.2215/CJN.02680314.
    1. Letizia C., Mazzaferro S., de Ciocchis A., et al. Effects of haemodialysis session on plasma beta-endorphin, ACTH and cortisol in patients with end-stage renal disease. Scandinavian Journal of Urology and Nephrology . 2010;30(5):399–402. doi: 10.3109/00365599609181317.
    1. Tsuchida S., Sugawara H., Fukuchi S. Plasma cortisol level during hemodialysis with Kolff's artificial kidney. The Tohoku Journal of Experimental Medicine . 1970;100(1):23–29. doi: 10.1620/tjem.100.23.
    1. Moher D., Hopewell S., Schulz K. F., et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ . 2010;340 doi: 10.1136/bmj.c869.
    1. Hägg E., Asplund K., Lithner F. Value of basal plasma cortisol assays in the assessment of pituitary-adrenal insufficiency. Clinical Endocrinology . 1987;26(2):221–226. doi: 10.1111/j.1365-2265.1987.tb00780.x.
    1. Derendorf H., Möllmann H., Barth J., Möllmann C., Tunn S., Krieg M. Pharmacokinetics and oral bioavailability of hydrocortisone. Journal of Clinical Pharmacology . 1991;31(5):473–476. doi: 10.1002/j.1552-4604.1991.tb01906.x.
    1. Yoon J. W., Lee Y. K., Choi M. J., Ryu J. W., Koo J. R., Noh J. W. FP730PREVALENCE of adrenal insufficiency and method of ACTH stimulation in chronic hemodialysis patients. Nephrology Dialysis Transplantation . 2015;30(Supplement 3) doi: 10.1093/ndt/gfv183.48.
    1. Yanase T., Tajima T., Katabami T., et al. Diagnosis and treatment of adrenal insufficiency including adrenal crisis: a Japan Endocrine Society clinical practice guideline [opinion] Endocrine Journal . 2016;63(9):765–784. doi: 10.1507/endocrj.EJ16-0242.
    1. Sułowicz W., Radziszewski A. Dialysis induced hypotension--a serious clinical problem in renal replacement therapy. Medicinski Pregled . 2007;60(Supplement 2):14–20.
    1. Knoll G. A., Grabowski J. A., Dervin G. F., O'Rourke K. A randomized, controlled trial of albumin versus saline for the treatment of intradialytic hypotension. Journal of the American Society of Nephrology . 2004;15(2):487–492. doi: 10.1097/01.asn.0000108971.98071.f2.
    1. Hammes M., Bakris G. L. Intradialytic hypotension: is midodrine the answer? American Journal of Nephrology . 2018;48(5):378–380. doi: 10.1159/000494805.
    1. Hussein W. F., Schiller B. Dialysate sodium and intradialytic hypotension. Seminars in Dialysis . 2017;30(6):492–500. doi: 10.1111/sdi.12634.
    1. Bullen A., Rifkin D., Trzebinska D. Individualized cool dialysate as an effective therapy for intradialytic hypotension and hemodialysis patients’ perception. Therapeutic Apheresis and Dialysis . 2019;23(2):145–152. doi: 10.1111/1744-9987.12761.
    1. Seo Y., Jeung S., Kang S. M., Yang W. S., Kim H., Kim S. B. Use of fludrocortisone for intradialytic hypotension. Kidney Research and Clinical Practice . 2018;37(1):85–88. doi: 10.23876/j.krcp.2018.37.1.85.
    1. De Souza S. P., Bezerra R., Andrade L., Seguro A. C. Combined therapy with dialysis and glucocorticoids in critically ill renal failure patients. Nephrology Dialysis Transplantation . 2006;21(7):1996–1998. doi: 10.1093/ndt/gfl085.
    1. Oray M., Abu Samra K., Ebrahimiadib N., Meese H., Foster C. S. Long-term side effects of glucocorticoids. Expert Opinion on Drug Safety . 2016;15(4):457–465. doi: 10.1517/14740338.2016.1140743.
    1. Hoes J. N., Jacobs J. W., Boers M., et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Annals of the Rheumatic Diseases . 2007;66(12):1560–1567. doi: 10.1136/ard.2007.072157.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe